We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
Viking Therapeutics, Inc. (VKTX - Free Report) closed the most recent trading day at $25.76, moving -2.35% from the previous trading session. This move lagged the S&P 500's daily loss of 1.21%. Meanwhile, the Dow gained 0.02%, and the Nasdaq, a tech-heavy index, lost 2.6%.
Coming into today, shares of the company had lost 36.66% in the past month. In that same time, the Medical sector gained 2.71%, while the S&P 500 lost 0.03%.
Market participants will be closely following the financial results of Viking Therapeutics, Inc. in its upcoming release. The company plans to announce its earnings on October 28, 2026. The company's upcoming EPS is projected at -$1, signifying a 23.46% drop compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of -$4.46 per share and a revenue of $0 million, demonstrating changes of -39.81% and 0%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Viking Therapeutics, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.16% higher within the past month. Currently, Viking Therapeutics, Inc. is carrying a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 105, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX - Free Report) closed the most recent trading day at $25.76, moving -2.35% from the previous trading session. This move lagged the S&P 500's daily loss of 1.21%. Meanwhile, the Dow gained 0.02%, and the Nasdaq, a tech-heavy index, lost 2.6%.
Coming into today, shares of the company had lost 36.66% in the past month. In that same time, the Medical sector gained 2.71%, while the S&P 500 lost 0.03%.
Market participants will be closely following the financial results of Viking Therapeutics, Inc. in its upcoming release. The company plans to announce its earnings on October 28, 2026. The company's upcoming EPS is projected at -$1, signifying a 23.46% drop compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of -$4.46 per share and a revenue of $0 million, demonstrating changes of -39.81% and 0%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Viking Therapeutics, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.16% higher within the past month. Currently, Viking Therapeutics, Inc. is carrying a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 105, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.